Amylyx Pharmaceuticals (AMLX) is back in focus after disclosing a proposed $6.5 million settlement of a securities class action covering buyers between November 2022 and November 2023, a development that may affect how you view legal overhangs.

The share price has been under pressure recently, with a 1-day share price return of down 6.92% and a 30-day share price return of down 9.57%. However, the year-to-date share price return of 16.64% alongside a 1-year total shareholder return of about 2.4x suggests longer term momentum has been stronger, even as legal headlines reset risk perceptions.

If this legal update has you reassessing your watchlist, it can help to see how other healthcare names are trading, especially those exposed to AI driven drug development, using the 38 healthcare AI stocks

With Amylyx trading at US$13.32 and screens suggesting a sizable discount to some analyst and intrinsic value estimates, the key question is whether current legal and clinical risks create an opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 40% Undervalued

At a last close of $13.32 versus a narrative fair value of $22.20, the current price sits well below what the most followed model suggests.

The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.

Curious how a company with no revenue today arrives at that higher fair value. The narrative leans heavily on future GLP 1 driven sales and a lofty earnings multiple. It can be useful to review which growth and margin assumptions would need to hold to bridge that gap.

Result: Fair Value of $22.20 (UNDERVALUED)

However, this story still hinges on a single pivotal PBH trial and heavy pipeline spending; weak LUCIDITY data or higher funding needs could quickly upend it.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich On Book Value

The SWS DCF model points to undervaluation, yet the P/B ratio of 5.4x looks expensive beside the US Pharmaceuticals average of 2.2x and a peer average of 3.2x. That gap highlights real valuation risk if sentiment toward loss making biotech stocks cools again. How comfortable are you with that trade off?

Next Steps

The mix of legal, clinical and valuation signals here is finely balanced, so it makes sense to move quickly and weigh the trade off yourself using our breakdown of 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If Amylyx is on your radar, do not stop there. Broaden your watchlist with a few targeted stock ideas that might otherwise slip past you.

• Start with value and scan a curated set of 48 high quality undervalued stocks that combine quality traits with prices that screen below their implied worth.
• Prioritise resilience and focus on solid balance sheet and fundamentals stocks screener (46 results) so you can concentrate on businesses with stronger financial footing.
• Hunt for potential outliers and surface a screener containing 21 high quality undiscovered gems that may not yet be crowded with attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.